EU/3/18/2038:

Palovarotene

Overview

On 27 June 2018, orphan designation (EU/3/18/2038) was granted by the European Commission to PPD Global Ltd, United Kingdom, for palovarotene for the treatment of multiple osteochondromas.

The sponsorship was transferred to PPD Bulgaria EOOD, Bulgaria, in April 2019 and subsequently to Ipsen Pharma, France, in May 2021.

Key facts

Active substance
Palovarotene
Intented use
Treatment of multiple osteochondromas
Date of designation
27/06/2018
Orphan designation status
Positive
EU designation number
EU/3/18/2038

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

65 Quai Georges Gorse
92100 Boulogne Billancourt
France
Tel. +33 1 58 33 54 27
E-mail : abdelali.majdi@ipsen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating